linagliptin glp 1 GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome Mechanism of action for GIP,

This study defined glutathione as a first line of defense against oxidative stress

Anna was diagnosed with depression 20 years ago, and treated her symptoms successfully

A A Does Botox for migraine cause cosmetic changes

Type 2 diabetes mellitus (DM2) is a major problem because of its high and increasing prevalence throughout the world and the personal and financial costs associated with the disease.1 Appropriate management, including lifestyle and pharmacological measures, has been shown to reduce DM2 related mortality2 and complications.3 The aim of reducing the adverse effects of the traditional therapeutic agents, as well as the need for different treatment options for such a complex and diverse disease, has greatly stimulated the development of new drugs.4 In 2010, the Steering Committee of the Spanish Society of Diabetes (Sociedad Espaola de Diabetes [SED]) commissioned the Consensus and Clinical Guidelines Working Group (Grupo de Trabajo de Consensos y Guas Clnicas [GTCGC]) to prepare a document embodying as far as possible the available evidence and the different recommendations regarding the situation of diabetes in Spain.5 The idea was to update this document regularly according to the emerging evidence and the suggestions of the members of the SED

Read on for key insights to help you lose fat and stay healthy while on a GLP-1 medication